BIO-TECHNE Corp — Director's Dealing 2020

May 26, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2020-05-21

Reporting Person: BAUMGARTNER ROBERT V (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-21	Common Stock	M	5000	$70.35	Acquired	14221	Direct
2020-05-21	Common Stock	S	1300	$265.3537	Disposed	12921	Direct
2020-05-21	Common Stock	S	1601	$266.0706	Disposed	11320	Direct
2020-05-21	Common Stock	S	1974	$267.3178	Disposed	9346	Direct
2020-05-21	Common Stock	S	125	$267.9406	Disposed	9221	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-21	Stock Options (right to Buy)	$70.35	M	5000	Disposed	2021-10-26	Common Stock (5000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (right to buy)	$66.90	2022-10-24	Common Stock (5000)	5000	Direct
Stock Options (right to buy)	$87.39	2023-10-30	Common Stock (4000)	4000	Direct
Stock Options (right to buy)	$91.78	2024-10-30	Common Stock (4000)	4000	Direct
Stock Options (right to buy)	$87.34	2025-10-28	Common Stock (4260)	4260	Direct
Stock Options (right to buy)	$101.19	2026-10-26	Common Stock (3985)	3985	Direct
Stock Options (right to buy)	$125.05	2027-10-26	Common Stock (3125)	3125	Direct
Stock Options (right to buy)	$179.84	2028-10-25	Common Stock (1898)	1898	Direct
Stock Options (right to buy)	$201.64	2029-10-24	Common Stock (2011)	2011	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.64 to $265.6276, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.68 to $266.6712, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.82 to $267.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.82 to $267.97, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders.